Arbutus Biopharma (LTS:0SGC) Construction In Progress: $0.0 Mil (As of Mar. 2026)


LTS:0SGC Arbutus Biopharma Corp LTS:0SGC
53 GF Score
Price $3.32
GF Value $34.87
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Construction In Progress?

Arbutus Biopharma LTS:0SGC 53 Construction In Progress is $0.0 Mil as of Mar. 2026. GuruFocus rates LTS:0SGC with a GF Score™ of 53/100 and a GF Value™ of $34.87. The stock has 5 warning signs investors should review.

Arbutus Biopharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma Construction In Progress Chart

Arbutus Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arbutus Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0SGC
53GF Score
Arbutus Biopharma Corp LTS:0SGC
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.0 Mil mean?
Arbutus Biopharma (LTS:0SGC) has a Construction In Progress of $0.0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's Construction In Progress too high?
Arbutus Biopharma's current Construction In Progress is $0.0 Mil. Overall, Arbutus Biopharma has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Construction In Progress compare to EVMN and ANNX?
Arbutus Biopharma's Construction In Progress of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Arbutus Biopharma and its competitors. Arbutus Biopharma's current Construction In Progress is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Arbutus Biopharma (LTS:0SGC) has a current Construction In Progress of $0.0 Mil. The stock's GF Value™ is $34.87, compared to a current price of $3.32 — trading 90.5% below its estimated fair value. The current Construction In Progress is $0.0 Mil. Arbutus Biopharma's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Arbutus Biopharma (LTS:0SGC), the current Construction In Progress is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (LTS:0SGC) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $3.32 is trading 90.5% below its estimated GF Value™ of $34.87.

Key valuation signals for LTS:0SGC:

  • Construction In Progress: $0.0 Mil
  • GF Value™: $34.87 vs. price of $3.32 (90.5% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the LTS:0SGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges ABUS:USAI9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for LTS:0SGC

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.32
Price
$34.87
GF Value